Safety and Efficacy of Amlotinib in the Treatment of Recurrent Craniopharyngioma

Get Involved

Safety and Efficacy of Amlotinib in the Treatment of Recurrent Craniopharyngioma

Study Purpose

Primary Aim: To assess the objective remission rate (ORR) of patients with recurrent craniopharyngiomas treated with amrlotinib . Secondary Aims: 1. To assess progression-free survival (PFS) and overall survival (OS) of patients with recurrent craniopharyngiomas treated with amrlotinib. 2. To analyze the disease control rate (DCR) of the Anrotinib treatment regimen in patients with recurrent craniopharyngiomas, including the proportion of patients in complete remission, partial remission and stable disease. 3. Monitor and evaluate the safety of amrutinib, especially the occurrence of drug-related adverse events (AEs) .

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	No
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Interventional
Eligible Ages	18 Years - 75 Years
Gender	All

More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Age 18-75 years old, regardless of gender. 2. recurrent craniopharyngioma (recurrence after total resection or regrowth of residual tumor) confirmed by pathology and imaging data. 3. predominantly cystic or solid recurrence of the tumor. 4. measurable lesions (according to the RECIST criteria) 5. Karnofsky score ≥ 70, expected survival ≥ 3 months. 6. laboratory parameters (liver and kidney function, blood tests, etc.) within the normal range or under control. 7. signed informed consent and willing to participate in the study.

Exclusion Criteria:

1. Have a combination of other intracranial tumors or severe brain lesions. 2. primary craniopharyngioma. 3. have severe uncontrolled heart, lung, kidney, or liver disease. 4. children, pregnant or breastfeeding women. 5. prior treatment with the same investigational drug. 6. active infections, including HIV, HBV, or HCV infections. 7. patients who do not meet the contraindications to the medication. 8. have a history of severe allergy to the investigational drug. 9. have psychiatric illnesses or cognitive impairments and unable to complete follow-up visits or understand the purpose of the study

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT06970145
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.	Phase 1/Phase 2
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Nanfang Hospital, Southern Medical University
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	N/A
Principal Investigator Affiliation	N/A
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Other
Overall Status	Recruiting
Countries	China
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Craniopharyngiomas

Additional Details

This study is a single-center, open-label, single-arm clinical trial designed to evaluate the safety and efficacy of amlotinib in the treatment of recurrent craniopharyngioma. Primary endpoints include progression-free survival (PFS), overall survival (OS), and objective remission rate (ORR), with assessment of treatment-related adverse events and quality of life. Analysis Set: Full Analysis Set (FAS): includes all patients who are randomized into the study, have received at least received at least one dose of study drug and have measurable baseline tumors.FAS will be used for efficacy FAS will be used for efficacy analysis. Per-Protocol Set (PPS): In the FAS, patients with at least one post-dose tumor imaging evaluation and a compliant tumor. PPS: In the FAS, patients with at least one post-dose tumor imaging assessment, good compliance, and no significant violations or deviations from the trial protocol. PPS will be used for secondary efficacy analysis. Safety Set (SS): Includes all patients who have received at least one dose of drug therapy and have completed at least one safety assessment. SS will be used for safety analysis. Sample size determination: This is an experimental clinical study with the primary objective of assessing the safety and preliminary efficacy of the drug. The sample size was designed to be relatively small due to resource constraints and the nature of experimental clinical studies. Based on the literature references and study design, we expected to enroll approximately 57 subjects. Statistical analysis All statistical analyses will be performed using SAS 9.2 statistical analysis software. Separate independent efficacy and safety analyses will be performed, and no control will be established. efficacy and safety analyses will be performed separately, with no control group and no between-group comparisons.ORR and DCR will be described using frequency and percentage, PFS and OS will be described using frequency and percentage. ORR and DCR were described using frequency and percentage, PFS and OS were estimated by Kaplan-Meier method for survival, and All treatment-related adverse events were recorded and analyzed according to CTCAE 5.0 criteria.

Arms & Interventions

Arms

Experimental: A single-center, open-label, single-arm, experimental clinical trial without any control group

This is a single-center, open-label, single-arm, experimental clinical trial without any control group. The study was conducted in patients with recurrent craniopharyngiomas

Interventions

Drug: - Anlotinib

Anlotinib Hydrochloride Capsules (12mg),Chiatai Tianqing Pharma (China).

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.